$晶泰控股-P(02_老虎社区_美港股上老虎

精灵魔法
05-23

$晶泰控股-P(02228)$ SIGX1094是晶泰控股与希格生科合作研发的基于“类器官+AI”药物研发平台开发的核心产品，主要用于治疗弥漫性胃癌及其他晚期实体瘤，也是全球首个进入临床阶段的FAK/SRC双靶点抑制剂，目前进入一期临床阶段，获得FDA孤儿药、快速通道认定

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":438036869587048,"tweetId":"438036869587048","gmtCreate":1747977975912,"gmtModify":1747980669277,"author":{"id":4108170727081450,"idStr":"4108170727081450","authorId":4108170727081450,"authorIdStr":"4108170727081450","name":"精灵魔法","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":37,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02228\">$晶泰控股-P(02228)$ </a> SIGX1094是晶泰控股与希格生科合作研发的基于“类器官+AI”药物研发平台开发的核心产品，主要用于治疗弥漫性胃癌及其他晚期实体瘤，也是全球首个进入临床阶段的FAK/SRC双靶点抑制剂，目前进入一期临床阶段，获得FDA孤儿药、快速通道认定</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02228\">$晶泰控股-P(02228)$ </a> SIGX1094是晶泰控股与希格生科合作研发的基于“类器官+AI”药物研发平台开发的核心产品，主要用于治疗弥漫性胃癌及其他晚期实体瘤，也是全球首个进入临床阶段的FAK/SRC双靶点抑制剂，目前进入一期临床阶段，获得FDA孤儿药、快速通道认定</p></body></html>","text":"$晶泰控股-P(02228)$ SIGX1094是晶泰控股与希格生科合作研发的基于“类器官+AI”药物研发平台开发的核心产品，主要用于治疗弥漫性胃癌及其他晚期实体瘤，也是全球首个进入临床阶段的FAK/SRC双靶点抑制剂，目前进入一期临床阶段，获得FDA孤儿药、快速通道认定","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/438036869587048","repostId":0,"isVote":1,"tweetType":1,"viewCount":454,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02228"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":231,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}